Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 4 1Phase 1 1

Status

Withdrawn 2Recruiting 2Terminated 1Completed 1

Sponsor Class

INDUSTRY 6OTHER 4

Study Type

Interventional 6

Sponsor

Cancer Type

Other hematologic neoplasm 6Myeloid 2Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 6Myelodysplastic Syndromes 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neutropenia 1Neoplasms 1Neoplasm, Residual 1Myelodysplastic-Myeloproliferative Diseases 1Mycoses 1Leukemia, Myeloid 1

Interventions

Azacitidine 142Cytarabine 109venetoclax 94fludarabine 35Daunorubicin 34Decitabine 32Idarubicin 26gilteritinib 24Cyclophosphamide 21quizartinib 15midostaurin 15Mitoxantrone 14Etoposide 14Granulocyte Colony-Stimulating Factor 12Gemtuzumab 11CPX-351 11decitabine and cedazuridine drug combination 10Drug Therapy 10cc-486 9Filgrastim 9Clofarabine 9ivosidenib 8Injections 8Dexamethasone 8pevonedistat 7fludarabine phosphate 7AP 1903 reagent 7posaconazole 6magrolimab 6glasdegib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia, Myeloid, Acute × posaconazole × Clear all
NCT07155226 2026-05-19

MOMENTUM

AstraZeneca

Phase 1/2 Recruiting
84 enrolled
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04771130 2026-04-23

A Study of BGB-11417 in Participants With Myeloid Malignancies

BeOne Medicines

Phase 1/2 Recruiting
260 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases

NCT02203773 2023-05-16

Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)

AbbVie

Phase 1 Terminated
212 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Leukemia, Myeloid, Acute

NCT03760445 2020-01-09

HDM201 Added to CT in R/R or Newly Diagnosed AML

Novartis

Phase 1/2 Withdrawn
Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT03036046 2018-02-15

SAFEGUARDFP

F2G Biotech GmbH

Phase 1/2 Withdrawn
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00686543 2017-04-07

Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115)

Merck Sharp & Dohme LLC

Phase 4 Completed
75 enrolled 14 charts
Other hematologic neoplasm

Mycoses, Neutropenia, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡